Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 7;16(1):85–94. doi: 10.1007/s11523-020-00778-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig. 1 — Sample selection. cHL classical Hodgkin lymphoma, GPI Generic Product Identifier, HCPCS Healthcare Common Procedure Coding System, ICD-9-CM International Classification of Diseases, 9th Revision, Clinical Modification, ICD-10-CM International Classification of Diseases, 10th Revision, Clinical Modification, NLPHL nodular lymphocyte-predominant Hodgkin lymphoma. 1 Patients who received both treatments and who initiated nivolumab prior to pembrolizumab approval or in the first months after were classified in the pembrolizumab cohort. Patients with an index treatment of pembrolizumab prior to nivolumab were considered as part of the pembrolizumab cohort (i.e., cohorts were mutually exclusive). 2 Pembrolizumab (GPI: 2135305300; HCPCS: J9271) and nivolumab (GPI: 2135304100; HCPCS: J9299) were identified from pharmacy and procedure claims. 3 Diagnosis of cHL in the primary or secondary position (ICD-9-CM: 201.0x–201.2x, 201.5x–201.9x; ICD-10-CM: C81.1x–C81.9x). 4 Diagnosis of NLPHL in the primary or secondary position (ICD-9-CM: 201.4x; ICD-10-CM: C81.0x)